Intralesional Bleomycin Combined With Cryotherapy in the Treatment of Recalcitrant Verruca Vulgaris
BleomycinVerruca vulgaris is a common cutaneous manifestation of Human Papillomavirus (HPV) infection that presents as hyperkeratotic, cauliflower-like papules with central black petechiae. These lesions may be resistant to conventional therapies, posing a therapeutic challenge and prolong significant morbidity for the patient. This case report demonstrates an immediate and robust response of recalcitrant …
Bleomycin
JDD Issue Highlights | April 2022
psoriasisThe April 2022 issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and editorials. With topics ranging from injectable fillers, botulinum toxin in hidradenitis suppurativa, cannabis and cannabinoid product use, to psoriasis, melasma, onychomycosis and everything in between, we share this month’s issue highlights straight from the JDD …
psoriasis
Laboratory Testing in Telogen Effluvium
Telogen Effluvium (TE) Telogen effluvium (TE) – a common cause of non- scarring hair loss – is managed with varying clinical protocols given the paucity of evidence-based practices. INTRODUCTION Telogen effluvium (TE) – a common cause of non-scarring hair loss – is managed with varying clinical protocols given the paucity of evidence-based practices. While endocrine, vitamin, and mineral abnormalities …
Telogen Effluvium (TE)
Hydroquinone Therapeutic Cheat Sheet
hydroquinoneHydroquinone is the most commonly used depigmentation agent and is a first-line treatment for melasma.1Hydroquinone was available previously in over-the-counter products and is currently available in prescription formulations with common concentration ranges of 0.4 to 5%. Prescription strengths available in the United States include hydroquinone 2% and 4% cream and hydroquinone 2% gel.2,3 In Septe …
hydroquinone
What’s New in Atopic Dermatitis
atopic dermatitisNext Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Adam Friedman (Professor and Chair of Dermatology who serves as Associate Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Program in the GW Department of Dermatology) about the latest in Atopic Dermatitis (AD). Watch as he discu …
atopic dermatitis
error

Enjoy this blog? Please spread the word :)